LPRS2
MCID: LPR022
MIFTS: 34

Leprosy 2 (LPRS2)

Categories: Endocrine diseases, Eye diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Leprosy 2

MalaCards integrated aliases for Leprosy 2:

Name: Leprosy 2 57 29 6
Leprosy, Susceptibility to, 2 57 70
Leprosy, Type 2 39
Leprosy 70
Lprs2 57

Classifications:



External Ids:

OMIM® 57 607572
UMLS 70 C0023343 C1843632

Summaries for Leprosy 2

MalaCards based summary : Leprosy 2, also known as leprosy, susceptibility to, 2, is related to leprosy 3 and hansen's disease. An important gene associated with Leprosy 2 is PRKN (Parkin RBR E3 Ubiquitin Protein Ligase), and among its related pathways/superpathways are cAMP signaling pathway and Neuroscience. The drugs Levoleucovorin and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin.

More information from OMIM: 607572

Related Diseases for Leprosy 2

Diseases in the Leprosy 3 family:

Leprosy 2 Leprosy 1
Leprosy 4 Leprosy 5
Leprosy 6

Diseases related to Leprosy 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
# Related Disease Score Top Affiliating Genes
1 leprosy 3 10.4
2 hansen's disease 10.4
3 endocrine pancreas disease 10.0 VIP CALCA
4 cluster headache 10.0 VIP CALCA
5 pancreatic cholera 10.0 VIP CALCA
6 vasomotor rhinitis 10.0 VIP CALCA
7 autonomic nervous system benign neoplasm 9.9 VIP CALCA
8 peripheral nervous system benign neoplasm 9.9 VIP CALCA
9 vipoma 9.9 VIP CALCA
10 somatostatinoma 9.9 VIP CALCA
11 ileus 9.9 VIP CALCA
12 islet cell tumor 9.9 VIP CALCA
13 lepromatous leprosy 9.9
14 neutropenia 9.9
15 chromoblastomycosis 9.9
16 mucormycosis 9.9
17 small cell cancer of the lung 9.9 VIP CALCA
18 intracranial vasospasm 9.9 VIP NPY
19 multiple endocrine neoplasia 9.9 VIP CALCA
20 rhinitis 9.8 VIP NPY
21 migraine with aura 9.8 VIP CALCA
22 ganglioneuroblastoma 9.8 VIP NPY
23 neuroendocrine tumor 9.8 VIP CALCA
24 perianal hematoma 9.8 NPY CALCA
25 carcinoid syndrome 9.8 NPY CALCA
26 reflex sympathetic dystrophy 9.8 NPY CALCA
27 achalasia 9.8 VIP NPY
28 normal pressure hydrocephalus 9.8 VIP NPY
29 autonomic nervous system disease 9.8 NPY CALCA
30 stuttering 9.8 VIP NPY
31 complex regional pain syndrome 9.8 NPY CALCA
32 rabies 9.8 VIP NPY
33 degenerative disc disease 9.8 NPY CALCA
34 tuberculoid leprosy 9.8
35 adult respiratory distress syndrome 9.7 VIP CALCA
36 fibromyalgia 9.7 NPY CALCA
37 machado-joseph disease 9.7 PRKN NPY
38 gastroesophageal reflux 9.7 VIP NPY
39 constipation 9.5 VIP NPY CALCA
40 migraine with or without aura 1 9.5 VIP NPY CALCA
41 hirschsprung disease 1 9.5 VIP NPY CALCA
42 peripheral nervous system disease 9.5 PRKN NPY CALCA
43 pheochromocytoma 9.5 VIP NPY CALCA
44 hypertension, essential 9.2 VIP NPY CALCA
45 disease of mental health 9.2 VIP PRKN NPY CALCA
46 asthma 9.1 VIP NPY CALCA

Graphical network of the top 20 diseases related to Leprosy 2:



Diseases related to Leprosy 2

Symptoms & Phenotypes for Leprosy 2

Clinical features from OMIM®:

607572 (Updated 05-Apr-2021)

Drugs & Therapeutics for Leprosy 2

Drugs for Leprosy 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
4 Vitamins Phase 4
5 Anti-Bacterial Agents Phase 4
6 Anti-Infective Agents Phase 4
7 Antitubercular Agents Phase 4
8 Antibiotics, Antitubercular Phase 4
9 Folic Acid Antagonists Phase 4
10 Vitamin B9 Phase 4
11 Folate Phase 4
12 Vitamin B Complex Phase 4
13 Antimalarials Phase 4
14 Antiparasitic Agents Phase 4
15 Antiprotozoal Agents Phase 4
16
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
17
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
18
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
19
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
20
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
21
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
22
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
23
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
24
Amitriptyline Approved Phase 3 50-48-6 2160
25
Perphenazine Approved Phase 3 58-39-9 4748
26
Bedaquiline Approved Phase 2, Phase 3 843663-66-1
27
Moxifloxacin Approved, Investigational Phase 2, Phase 3 354812-41-2, 151096-09-2 152946
28
Linezolid Approved, Investigational Phase 2, Phase 3 165800-03-3 441401
29
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
30 Hormone Antagonists Phase 2, Phase 3
31 Hormones Phase 2, Phase 3
32 Immunosuppressive Agents Phase 2, Phase 3
33 Methylprednisolone Acetate Phase 2, Phase 3
34 Cyclosporins Phase 2, Phase 3
35 Immunologic Factors Phase 2, Phase 3
36 Antirheumatic Agents Phase 2, Phase 3
37 Antineoplastic Agents, Hormonal Phase 2, Phase 3
38 glucocorticoids Phase 2, Phase 3
39 Dermatologic Agents Phase 2, Phase 3
40 Calcineurin Inhibitors Phase 2, Phase 3
41 Antifungal Agents Phase 2, Phase 3
42 Neurotransmitter Agents Phase 3
43 Narcotics Phase 3
44 Psychotropic Drugs Phase 3
45 Antidepressive Agents Phase 3
46 Analgesics, Non-Narcotic Phase 3
47 Analgesics Phase 3
48 Amitriptyline, perphenazine drug combination Phase 3
49 Analgesics, Opioid Phase 3
50 Adrenergic Agents Phase 3

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Effect of Additional Clofazimine on ENL Reactions in Leprosy Completed NCT01290744 Phase 4 Clofazimine;Placebo
3 Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
4 Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers Completed NCT01165840 Phase 4 Dapsone
5 A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions Completed NCT00919815 Phase 2, Phase 3 Ciclosporin;Prednisolone
6 Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial Recruiting NCT03942354 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Directly observed therapy (DOT)
7 Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD) Recruiting NCT04081077 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine
8 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Recruiting NCT03662022 Phase 3 Rifampicin
9 Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study Recruiting NCT03324035 Phase 3 Amitriptyline;Placebo oral capsule;Tramadol
10 Economic Evaluation of New MDR TB Regimens (PRACTECAL EE) Not yet recruiting NCT04207112 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Standard Drugs
11 Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region Completed NCT00128193 Phase 2
12 A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone. Completed NCT00919451 Phase 2 ciclosporin
13 A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only. Completed NCT00919776 Phase 2 prednisolone;ciclosporin
14 A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone. Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
15 An Open-Label Study to Evaluate the Efficacy and Safety of TMC207 in Subjects With Multibacillary Leprosy Recruiting NCT03384641 Phase 2 Bedaquiline 200 mg
16 A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
17 A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy Withdrawn NCT03947437 Phase 1, Phase 2
18 The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study Withdrawn NCT01885611 Phase 1, Phase 2
19 Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
20 Proposal Evaluation and Intervention Through Prevention of Disability in Leprosy Patients Completed NCT01006759 Phase 1
21 Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Completed NCT01920750 Phase 1
22 A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects Completed NCT03302897 Phase 1
23 Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy Unknown status NCT00406861 montelukast in treatment of ENL reaction
24 Evaluation of Low Level Laser Therapy Effects in Peripheral Nerves Patient Affected With Leprosy : Randomized Controlled Trial Unknown status NCT03072004
25 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Unknown status NCT03683745
26 Molecular Epidemiology of Leprosy in Colombia Completed NCT00138437
27 Observation of Microcirculation Impairment in Patients With Lepromatous Leprosy Using Orthogonal Polarization Spectral (OPS) Imaging and Laser Doppler Iontophoresis Completed NCT02085317 acetylcholine Iontophoresis;sodium nitroprusside Iontophoresis
28 Educational Virtual Objects (The Virtual Human Project) Assessment Inserted in Learning Based on Team (Team-based Learning) in Leprosy Education on Undergraduate Medical Setting Completed NCT02484469
29 Small Membrane Filtration (SMF) Method to Improve the Performance of Smear Microscopy for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting Completed NCT02701439
30 Molecular Epidemiology of Leprosy - Philippines Completed NCT00315809
31 Clinic-Epidemiological Evaluation of Ulcers in Leprosy Patients and the Use of Low Level Laser Therapy: a Randomized Clinical Trial Completed NCT00860717
32 Improved Understanding of Ongoing Transmission of Leprosy in the Comoros, a Region Hyperendemic for the Disease. Recruiting NCT03526718
33 Clofazamine in the Long Term Treatment of Leprosy, Phase III No longer available NCT00852345 clofazamine
34 Prospective Randomized Controlled Trial Comparing Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer. Terminated NCT01751503
35 CD8 Reactivity to Microorganisms in Blood and Breast Milk Terminated NCT03084614

Search NIH Clinical Center for Leprosy 2

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Thalidomide

Genetic Tests for Leprosy 2

Genetic tests related to Leprosy 2:

# Genetic test Affiliating Genes
1 Leprosy 2 29

Anatomical Context for Leprosy 2

MalaCards organs/tissues related to Leprosy 2:

40
Skin

Publications for Leprosy 2

Articles related to Leprosy 2:

(show all 44)
# Title Authors PMID Year
1
Linkage disequilibrium pattern and age-at-diagnosis are critical for replicating genetic associations across ethnic groups in leprosy. 57
23052943 2013
2
Association study of major risk single nucleotide polymorphisms in the common regulatory region of PARK2 and PACRG genes with leprosy in an Indian population. 57
16391553 2006
3
Susceptibility to leprosy is associated with PARK2 and PACRG. 57
14737177 2004
4
Chromosome 6q25 is linked to susceptibility to leprosy in a Vietnamese population. 57
12577057 2003
5
A major susceptibility locus for leprosy in India maps to chromosome 10p13. 57
11279529 2001
6
Genomic control for association studies. 57
11315092 1999
7
Study of S100 Immunostaining in Demonstrating Neural Granulomas in Paucibacillary Leprosy. 61
29937557 2018
8
Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum. 61
27556927 2016
9
Neuropathy in elderly: lessons learnt from nerve biopsy. 61
25362502 2015
10
Delusional infestation: a clinical profile. 61
23466108 2013
11
Patterns of migration and risks associated with leprosy among migrants in Maranhão, Brazil. 61
24040433 2013
12
[The current challenge of imported leprosy in Spain: a study of 7 cases]. 61
21334586 2011
13
[Epidemiological profile of leprosy in a Brazilian municipality between 2000 and 2006]. 61
20305971 2010
14
Leprosy. 61
19454067 2007
15
[Late-occurring cutaneous vasculitis after successful treatment of diffuse lepromatous leprosy: Lucio's phenomenon]. 61
17506277 2007
16
Increased prevalence of human T cell lymphotropic virus type 1 in patients attending a Brazilian dermatology clinic. 61
17622792 2007
17
Study of patients presenting with symptoms of peripheral neuropathy and thickened greater auricular nerve. 61
16340253 2003
18
Male-female (sex) differences in leprosy patients in south eastern Nigeria: females present late for diagnosis and treatment and have higher rates of deformity. 61
12449892 2002
19
Spectrum of dermatopathologic lesions associated with HIV/AIDS in India. 61
12785169 2002
20
Ocular manifestations of leprosy in a noninstitutionalized community in the United States. 61
8185519 1994
21
Denatured muscle grafts for nerve repair in an experimental model of nerve damage in leprosy. 2. Recovery of peripheral peptide-containing nerves assessed by quantitative immunohistochemical study. 61
7514642 1994
22
Intracardiac autonomic ganglion cells in leprosy and dilated cardiomyopathy. 61
8365740 1993
23
[Cutaneous neoplasms during leprosy: 2 case reports]. 61
1293912 1992
24
A study of morbidity pattern among prostitutes attending a municipal clinic in Pune. 61
2789264 1989
25
[Study on prevention of leprosy. 2. Chemo-prophylaxis trial for leprosy household contact children]. 61
3842969 1985
26
Leprosy. XII. T-cell subsets in lepromatous leprosy. 61
6983504 1982
27
Phagocytosis in leprosy. 2. Production of superoxide by circulating blood leukocytes from lepromatous patients. 61
215566 1978
28
Persistence of Australia antigen in leprosy--a frustrating puzzle in immunology. 61
651319 1978
29
The role of protein malnutrition in the pathogenesis of ulcerative "Lazarine" leprosy. 61
824211 1976
30
The histopathology of lepromatous leprosy in the nose. 61
1099180 1975
31
Acid mucopolysaccharide metabolism in leprosy. 2. Subcellular localization of hyaluronic acid and beta-glucuronidase in leprous infiltrates suggestive of a host-Mycobacterium leprae metabolic relationship. 61
4282081 1974
32
Experimental murine leprosy. 2. Further evidence for varying susceptibility of outbred mice and evaluation of the response of 5 inbred mouse strains to infection with Mycobacterium lepraemurium. 61
4604462 1974
33
Immunologic studies on leprosy. 2. Antigenic studies of Mycobacterium leprae. 61
4131110 1973
34
The control and management of leprosy. 2. 61
4496656 1973
35
Lipids in leprosy. 2. Histochemistry of lipids in human leprosy. 61
4102020 1970
36
Leprosy. 2. 61
5434944 1970
37
Nerves in the arm in leprosy. 2. Pathology, pathogenesis and clinical correlations. 61
4098603 1970
38
[Consideration and discussion of the pathogenesis of leprosy, with special reference to the influence of specific histological changes in the reticuloendothelial system on the progress of and recovery from leprosy. 2]. 61
5686369 1968
39
Studies on sulfone resistance in leprosy. 2. Treatment with a riminophenazine derivative (B.663). 61
6006070 1966
40
Epidemiology of disability in leprosy. 2. Factors associated with low disability. 61
5950068 1966
41
The facial nerve in leprosy. 2. Pathology, pathogenesis, electromyography and clinical correlations. 61
5950064 1966
42
Chemotherapeutic trials in leprosy. 2. Comparative trial of dapsone plus ditophal (Etisul) and dapsone alone in the treatment of lepromatous leprosy. 61
5322767 1965
43
[Relation between host resistance and disease type in mouse leprosy. 2. Influence of hyaluronidase on the onset of mouse leprosy]. 61
13751963 1961
44
Classification of leprosy, 2. The value of fat staining in classification. 61
13720258 1960

Variations for Leprosy 2

ClinVar genetic disease variations for Leprosy 2:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PRKN NM_004562.3(PRKN):c.823C>T (p.Arg275Trp) SNV Pathogenic 7050 rs34424986 GRCh37: 6:162206852-162206852
GRCh38: 6:161785820-161785820

Expression for Leprosy 2

Search GEO for disease gene expression data for Leprosy 2.

Pathways for Leprosy 2

Pathways related to Leprosy 2 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.59 VIP NPY
2 11.46 VIP PRKN NPY CALCA
3 11.32 VIP CALCA
4 10.49 NPY CALCA

GO Terms for Leprosy 2

Cellular components related to Leprosy 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 8.8 VIP PRKN CALCA

Biological processes related to Leprosy 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.58 VIP NPY CALCA
2 cellular protein metabolic process GO:0044267 9.43 PRKN CALCA
3 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.37 VIP CALCA
4 neuropeptide signaling pathway GO:0007218 9.32 NPY CALCA
5 positive regulation of protein catabolic process GO:0045732 9.26 VIP PRKN
6 regulation of blood pressure GO:0008217 9.16 NPY CALCA
7 feeding behavior GO:0007631 8.96 NPY CALCA
8 positive regulation of blood vessel diameter GO:0097755 8.62 VIP CALCA

Molecular functions related to Leprosy 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor binding GO:0001664 9.16 PRKN NPY
2 neuropeptide hormone activity GO:0005184 8.96 VIP NPY
3 hormone activity GO:0005179 8.8 VIP NPY CALCA

Sources for Leprosy 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....